Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Annexon Initiates $100 Million IPO Effort
11:00am, Saturday, 11'th Jul 2020
Annexon aims to raise $100 million in an IPO, although the final figure may differ. The firm is advancing treatments for various autoimmune and neurodegenerative disorders.
Stocks To Watch: Bank Earnings And SPAC Deals Blaze In
08:25am, Saturday, 11'th Jul 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Akcea Announces Appointment of New Chief Medical Officer
11:00am, Thursday, 09'th Jul 2020
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that William Andrews, MD, FACP, has joined the company as chief medical officer (CMO
Ionis Pharmaceuticals to hold neurology franchise webcast
11:05am, Tuesday, 07'th Jul 2020
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Tuesday, July 14th at 10:00 a.m. Eastern Time to review its neurology franchise. The approximately 90-min
Axa Has $4.20 Million Stock Position in Ionis Pharmaceuticals Inc (NASDAQ:IONS)
06:42am, Tuesday, 07'th Jul 2020
Axa lowered its stake in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 62.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fi
Oppenheimer Sticks to Its Buy Rating for Moleculin Biotech (MBRX) - Markets
04:54pm, Thursday, 02'nd Jul 2020
In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Moleculin Biotech (MBRX – Research Report),
Ionis Pharmaceuticals Inc (NASDAQ:IONS) Director Breaux Castleman Sells 10,000 Shares
04:52am, Wednesday, 01'st Jul 2020
Ionis Pharmaceuticals Inc (NASDAQ:IONS) Director Breaux Castleman sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average pri
C Frank Bennett Sells 15,000 Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) Stock
04:20am, Wednesday, 01'st Jul 2020
Ionis Pharmaceuticals Inc (NASDAQ:IONS) EVP C Frank Bennett sold 15,000 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $59.77, for a
Akebia Therapeutics (AKBA) Receives a Buy from Needham - Markets
02:54pm, Monday, 29'th Jun 2020
Needham analyst Chad Messer assigned a Buy rating to Akebia Therapeutics (AKBA – Research Report) today and set a price
Interpace Diagnostics Group (IDXG) Receives a Buy from Oppenheimer - Markets
03:51am, Friday, 26'th Jun 2020
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Interpace Diagnostics Group (IDXG – Research Report) yesterday and set a
Autolus Therapeutics (AUTL) Gets a Buy Rating from Needham - Markets
04:51pm, Thursday, 25'th Jun 2020
Needham analyst Chad Messer maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report) today and set a price
Personalis (PSNL) Gets a Buy Rating from Oppenheimer - Markets
04:19pm, Wednesday, 24'th Jun 2020
Oppenheimer analyst Kevin DeGeeter assigned a Buy rating to Personalis (PSNL – Research Report) today and set a price target
Ionis Pharmaceuticals, Inc. (IONS) Management Presents at BMO 2020 Prescriptions for Success Healthcare Conference Transcript
05:19pm, Tuesday, 23'rd Jun 2020
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) BMO 2020 Prescriptions for Success Healthcare Conference June 23, 2020, 02:00 PM ET Company Participants Eric Swayze -
Ionis Pharmaceuticals (IONS) Investor Presentation - Slideshow
04:17pm, Tuesday, 23'rd Jun 2020Oppenheimer Maintains Their Buy Rating on Vascular Biogenics (VBLT) - Markets
12:42am, Tuesday, 23'rd Jun 2020
Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Vascular Biogenics (VBLT – Research Report) yesterday and set a price
